D.A. Davidson & Co’s TG Therapeutics TGTX Stock Holding History

D.A. Davidson & Co’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,100	Closed	-$213K	–	1175
2020 Q4	$213K	Buy	+4,100	New	+$139K	﹤0.01%	952

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

D.A. Davidson & Co's TGTX Position: Q1 2021 in Review

D.A. Davidson & Co sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 4,100 shares — an estimated $213K sold.

D.A. Davidson & Co first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

D.A. Davidson & Co reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
D.A. Davidson & Co sold 4,100 TG Therapeutics shares in Q1 2021, an estimated $213K.
D.A. Davidson & Co first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
D.A. Davidson & Co's TG Therapeutics position peaked at $213K in Q4 2020.
240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on D.A. Davidson & Co's 13F filing for Q1 2021, filed 7 May 2021.